137 related articles for article (PubMed ID: 15827549)
1. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients.
Johnstone EC; Lind MJ; Griffin MJ; Boddy AV
Cancer Chemother Pharmacol; 2000; 46(6):433-41. PubMed ID: 11138456
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
5. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.
Hartley JM; Spanswick VJ; Gander M; Giacomini G; Whelan J; Souhami RL; Hartley JA
Clin Cancer Res; 1999 Mar; 5(3):507-12. PubMed ID: 10100700
[TBL] [Abstract][Full Text] [Related]
6. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
7. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
8. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
11. Progressive glomerular toxicity of ifosfamide in children.
Prasad VK; Lewis IJ; Aparicio SR; Heney D; Hale JP; Bailey CC; Kinsey SE
Med Pediatr Oncol; 1996 Sep; 27(3):149-55. PubMed ID: 8699991
[TBL] [Abstract][Full Text] [Related]
12. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
[TBL] [Abstract][Full Text] [Related]
13. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.
Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D
Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Passe P; Delepine N; Arnaud P; Urien S; Delepine G; Traoré F; Desbois JC; Brion F
Anticancer Res; 1999; 19(1B):837-42. PubMed ID: 10216502
[TBL] [Abstract][Full Text] [Related]
15. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
[TBL] [Abstract][Full Text] [Related]
16. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Brain EG; Rezai K; Weill S; Gauzan MF; Santoni J; Besse B; Goupil A; Turpin F; Urien S; Lokiec F
Cancer Chemother Pharmacol; 2007 Aug; 60(3):375-81. PubMed ID: 17106751
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide enantiomers: pharmacokinetics in children.
Prasad VK; Corlett SA; Abaasi K; Heney D; Lewis I; Chrystyn H
Cancer Chemother Pharmacol; 1994; 34(5):447-9. PubMed ID: 8070015
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A
Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics.
Hanly LN; Chen N; Aleksa K; Cutler M; Bajcetic M; Palassery R; Regueira O; Turner C; Baw B; Malkin B; Freeman D; Rieder MJ; Vasylyeva TL; Koren G
J Clin Pharmacol; 2012 Jan; 52(1):55-64. PubMed ID: 21263015
[TBL] [Abstract][Full Text] [Related]
20. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Brüggemann SK; Pfäffle S; Peters SO; Wagner T
Drug Metab Dispos; 2007 Oct; 35(10):1721-4. PubMed ID: 17600085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
